CSL shares bleed to decade low after $6.9 billion writedown as turnaround timeline blows out

Shares in Australian blood products giant CSL Limited (ASX: CSL) have crashed to a decade low after revealing US$5 billion ($6.9 billion) in additional non-cash impairments and a further downgrade to full-year earnings guidance, signalling the company's turnaround will take significantly longer…


Click here to view the original article.